- 1Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China
- 2School of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun, China
A Corrigendum on
Mechanism of Valeriana officinalis L. extract improving atherosclerosis by regulating PGC-1α/Sirt3/Epac1 pathway
by Yao B, Ma J, Ran Q, Chen H and He X (2024). Front. Pharmacol. 15:1483518. doi: 10.3389/fphar.2024.1483518
In the published article, there was an error in the Funding statement. Two important pieces of funding support [“the National Natural Science Foundation of China (No. 82205091)” and “Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences (CI2021A04619)”] were erroneously omitted. The correct Funding statement appears below.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by the National Natural Science Foundation of China (No. 82205091 and No. 82074396), the Clinical Research Funds for the Centralized High level Chinese Medicine Hospitals (HLCMHPP2023077), Scientific and Technological Innovation Project of China Academy of Chinese Medical Sciences (CI2023CO22YL and CI2021A04619).
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: Valeriana officinalis L., extract, atherosclerosis, PGC-1α/Sirt3/Epac1 pathway, mitochondrial damage, traditional Chinese medicine
Citation: Yao B, Ma J, Ran Q, Chen H and He X (2025) Corrigendum: Mechanism of Valeriana officinalis L. extract improving atherosclerosis by regulating PGC-1α/Sirt3/Epac1 pathway. Front. Pharmacol. 16:1607975. doi: 10.3389/fphar.2025.1607975
Received: 08 April 2025; Accepted: 10 April 2025;
Published: 24 April 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Yao, Ma, Ran, Chen and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Hengwen Chen, Y2hlbmhlbmd3ZW5AMTYzLmNvbQ==; Xuanhui He, aGV4dWFuemkxNjQ2QHNpbmEuY29t
†These authors have contributed equally to this work and share first authorship